Site Search

 

 

 

 

 

Home
General Topics
       What is Dialysis?
       Residual Renal Function
          The Importance of RRF
       Diabetes Management
          PD and the Diabetic Patient
          General Facts: Diabetes
       Renal Osteodystrophy
          Renal Osteodystrophy Clinical Studies
       Numbers-Their Use and Interpretation
       Basic Statistics
       Other
          Vaccinating CKD and Dialysis Patients
          32 yr dialysis patient receives Achievement award
Peritoneal Dialysis
       History of PD
          PD - The Foundations
          Early Clinical Experiences with PD
       Basic Principles of PD
          Anatomy of the Peritoneum
          Physiology of the Peritoneum
       Peritoneal Transport 
          Understanding Testing Methods
          Prognostic Value of Transport Status
          Peritoneal Function After Exposure to PD
       Modalities of Therapy
          PD Techniques
          PD Modalities
       PD Adequacy
          Prescribing Dialysis
             Targets of PD Prescription
             Determinants of Dose
             Exchange Volume and Position
             How to Reach the Goals
             Monitoring the PD Patient
             Evaluating the Patient as a Whole
             StdKt/V - Dose Equivalency
       Ultrafiltration
          Importance of Volume Control
          How to Achieve Adequate PD UF
       Clinical Procedures
       Complications
          Non-Infectious Complications of PD
          Peritoneal Dialysis-Related Infections
             Management of ESI
             Diagnosis and Treatment of Peritonitis 
       Dialysis Access
          The Evolution of PD Catheters
          Preop Management
          Placement of PD Catheters
          Intraoperative Management
          Post Operative Care and Management
          Complications of PD Catheters
       Clinical Outcomes
          Clinical outcomes of PD and HD
       Peritoneal Dialysis in Children
          Pediatric ESRD Incidence, Prevalence and Mortality
          Management of the pediatric patient on PD
          Utilization of PD for Acute Renal Failure and ESRD
          Prescription principles, adequacy and PET
          Additional care considerations: Nutrition, Growth,
       PD in the ICU
       Home Program Management
Hemodialysis
       History of Hemodialysis
       Kinetic Principles
          Impact of t & Kr on Kt/V
          StdKt/V - Dose Equivalency
       Modalities of Therapy
          Hemodialysis Regimens/Prescriptions
          Extracorporeal Modalities
       Home HD
          Introduction
          HD Regimens/Prescriptions
          The Influence of Dose, Time & Frequency
          Every other day HD (HD3.5)
          Time Versus Dialysis-Free Interval
          Benefits of Increased HD Frequency
          Increased Frequency – Other Modalities
          Potential Lifestyle Benefits of HD3.5
          Home Program Management
             Establishing a Home Program
       Intradialytic Complications
       Adequacy
          Difficulties in Prescribing Adequate Dialysis
       Sodium Modeling
       Hemodialysis Access
          Introduction to Vascular Access
          Overview of Arteriovenous Fistula
          Overview of Arteriovenous Grafts
          Overview of Central Venous Catheters
          Vascular Access Monitoring and Surveillance
       Access Complications
          Overview of Hemodialysis Complications
          AVF Stenosis
          Interventions for AVF and AVG Stenosis
          Primary Fistula Failure
          Catheter Related Bacteremia
Sorbent Technology
       History of Sorbent Technology
Seminars & Education
Educational Initiatives
Training Resources
       Kidney Options Kidney Options
       Patient Training Resources
       Training Resources for Professionals Training Resources for Professionals
Product Information
       Peritoneal Dialysis
          Fresenius Peritoneal Dialysis Connections
          WebEx Teleconference Workshops
       Hemodialysis
       Home Hemodialysis
Glossary
Links
       Journals
       Organizations
       Other Links
Contact Information
Calendar of Events
Contributors

Understanding Testing Methods

Print PDF

Patient treatment success in PD is dependent on the functional and morphological integrity of the peritoneal membrane.  Besides functional failure of the peritoneum, long-term PD may lead to anatomic changes in the peritoneal tissues such as neoangiogenesis, vasculopathy and fibrosis, sometimes causing peritoneal sclerosis.  Because of these changes peritoneal permeability varies widely between patients and can change significantly over time within an individual.  The peritoneal membrane changes, and as a consequence the peritoneal transport status, have been reported to play a major role in determining patients’ morbidity and mortality1.  In order to find an appropriate PD modality and prescription it is crucial to assess the actual peritoneal membrane transport status as accurately as possible.  Peritoneal membrane transport does not only refer to transport of solutes, e.g. uremic toxins and electrolytes, but also to fluid transport.  Since both elimination of uremic toxins and ultrafiltration account for adequacy, it is important that a test reliably assesses both parameters. 

 

Understanding the testing methods

 

Numerous techniques for measuring peritoneal transport are available.

Parameters measured

PET

PFT

PDC

24 hour batch

DATT

APEX

SPA

Peritoneal membrane transport

x

x

x

x

x

x

x

Total peritoneal clearance

 

x

x

x

 

 

 

Residual renal function

 

x

x

x

 

 

 

Ultrafiltration

x

x

x

x

 

 

x

Nutritional status

 

x

x

x

 

 

 

 

The PET (peritoneal equilibration test) was the first standardized method to quantify individual peritoneal membrane characteristics and to compare the individual results with larger populations2.  It requires the collection of peritoneal effluent samples at time intervals over four hours using a standard protocol and a mid-point blood sample as outlined in the Clinical procedure for PET.  The results are expressed as dialysate to plasma ratios (D/P) for the specific times for urea, creatinine and sodium or as dialysate dextrose concentration (Dt) at a certain time over dialysate dextrose concentration at time zero (D0) or immediately after infusion.  The results are plotted as D/P or Dt/D0 versus time in hours.  The values are categorized as high-average, high, low-average and low by using the mean of a large population + 1 and + 2 SD.  The PET has been serially repeated and found to be stable and reproducible over time. However, it is imperative to follow the test protocol rigorously in order to achieve reproducibility. 

 

Since the PET is very labor intensive, a modified or fast PET3 was designed to simplify the procedure, reduce cost and improve compliance with testing.  It requires only one dialysate sample, eliminates the supervised inflow procedure, the baseline and two hour measurements and substitutes dialysate glucose at 4 hours for the ratio of the 4 hour value to baseline glucose dialysate value (D4/D0).  The results of this single dialysate sample are interpreted using a standard table that classifies the data by transport categories.  The main limitations of the fast PET are the lack of internal controls and reproducibility Clinical procedure for fast PET

 

The original PET was standardized for a long overnight exchange since almost all patients were on CAPD and this was the most convenient approach.  Recent studies confirmed the minimal impact of the prior long exchange on small solute equilibration.  Thus, for clinical purposes, Twardowski, et al. introduced the short PET4 accepting any dwell time between 3 and 12 hours for the prior exchange and simplifying the test to include either a 2 or 4 hour dwell. Gotch, et al. have suggested that the procedural steps in the PET may actually overestimate peritoneal membrane transport and underestimate the variation in peritoneal transport that may occur under actual clinical conditions5.  Moreover, it is imperative to be aware that the PET alone does not give an assessment of total solute removal (adequacy).  Thus, the PET should be combined with a 24-hour collection for renal and peritoneal solute clearance.

 

The Peritoneal Function Test (PFT), developed by Gotch, et al. has been extensively used and validated in multicenter studies6,7. The test allows assessment of total delivered therapy for urea and creatinine, protein and calorie nutrition, fluid balance, and peritoneal transport.  Clinical procedure for PFT.  The results are expressed as Pt50 or the time required for a solute to achieve 50% equilibration between dialysate and plasma.  The PFT has been extensively used as part of a kinetic modeling program (Pack-PD® or Patient on-line [POL]) and the data can be displayed for individual patients, clinics or regional groups of dialysis centers. 

 

For follow up, a simplified PFT (SPFT) can be used. Clinical procedure for simplified PFT

 

The 24-hour batch dialysate test in combination with a simultaneous urine collection and a blood sample can provide a good measure of delivered dialysis dose8,9Clinical procedure for 24-hour batch dialysate test. The main disadvantage is the required collection of individual drains and their measurement.  Unless the patient is well trained and reliable, it is best to perform the measurements and sampling at the clinic.  According to one study, the 24-hr D/Pcreatinine correlates well with the PET transport information9.

 

The peritoneal dialysis capacity (PDC) program was designed to measure transperitoneal passage of fluid and solutes under normal conditions with a non-invasive test.  The PDC is based on the three-pore-model of Rippe, et al10,11.  It describes the peritoneal membrane characteristics by means of three parameters: 1) the area parameter A0/DX, which determines the diffusion of small solutes; 2) the final reabsorption rate of fluid from the abdominal cavity to blood when the glucose gradient has dissipated (JvAR); and 3) the large pore fluid flux (JVL) which determines the loss of protein to the PD fluid.  The PDC parameters are highly reproducible and the program can be used to achieve adequate dialysis and better understanding of the dynamics of PD exchanges. For the specific procedure protocol see reference 12. 

 

The dialysis adequacy and transport test (DATT) was introduced by Rocco et al. in an attempt to develop an easier test for classifying peritoneal transport type13,14.  Only a serum sample and a 10 ml aliquot from a pooled, well-mixed 24-hour dialysate are required for the calculation of the 24-hour D/P. Since the DATT has only been validated for patients on a fixed CAPD schedule of 4 two-liter exchanges, this test should only be used for patients on this prescription and should not be used for patients on cycler therapy15.

 

The accelerated peritoneal examination (APEX) test was designed by Verger et al. using a similar protocol as their initial equilibration test with 3.86% glucose solution, but summarizes in a single number the peritoneal permeability for both glucose and urea16.  It represents the time at which the glucose and urea equilibration curves cross.  Generally, the APEX may be shorter than a PET since most patients exhibit a crossing of the curves before 2 hours.  The shorter the APEX time, the higher the peritoneal permeability and, conversely, the longer the time, the lower the peritoneal permeability.  The APEX time may help to define the optimum contact time between the functional peritoneal membrane surface area and the dialysate for the individual patient.  If UF is the major goal, short dwell times should be used.  If solute clearance is the major goal, longer dwell times should be used.

 

The standard peritoneal permeability analysis (SPA) is a more sophisticated way to assess peritoneal function17.  It uses intraperitoneally administered dextran 70 to study fluid kinetics during a 4-hour dwell using an infusion volume consistent with the patient’s usual prescription.  The study is performed at the center over a period of 4 hours and requires two blood samples and many timed peritoneal effluent samples.  The SPA is useful in assessing MTAC of small solutes, clearance of proteins and changes in IP volume.   

 

For each test mentioned above it has to be considered that peritoneal transport characteristics change significantly within the first month of PD. Peritoneal function tests performed during this time should be seen as preliminary and should be confirmed by an additional test 4 weeks later18.  It is also important to recognize that peritoneal membrane function measurement - no matter if solute clearance or UF – is subject to error.  Therefore, one should be cautious with the interpretation of a single reading. 

 

Possible differences in peritoneal transport between children and adults have been discussed by many authors.  A recent study by Bouts, et al. did not confirm these concerns19.  The results suggest that the peritoneal membrane in children may not be different from that in adults.  Generally, all the tests mentioned above are also applicable in children using the appropriate exchange volume. 

 

It is unclear how often peritoneal function should be assessed.  The KDOQI guidelines recommend a measurement every 4 months20.  However, the tests are time-consuming for both patients and nurses and costly.  Ideally, one standard test used worldwide would be advisable, but since each test presently applied has its pros and cons, it is up to the Medical Director, which test best fits their needs.

 

 

References:

 

  1. Churchill DN, Thorpe KE, Nolph KD, et al. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 9:1285-1292, 1998
  2. Twardowski ZJ, Nolph KD, Khanna R, et al. Peritoneal equilibration test. Perit Dial Bull 7:138-47, 1987
  3. Twardowski ZJ. PET--a simpler approach for determining prescriptions for adequate dialysis therapy. Adv Perit Dial 6:186-191, 1990
  4. Twardowski ZJ, Prowant BF, Moore HL, et al. Short peritoneal equilibration test: impact of preceding dwell time. Adv Perit Dial 19:53-58, 2003
  5. Gotch F, Schoenfeld PY, Gentile DE.  The peritoneal equilibration test (PET) is not a realistic measure of peritoneal clearance (PC). J Am Soc Nephrol 2:361, 1991 (Abstract)
  6. Gotch FA and Keen ML. Kinetic modelling in peritoneal dialysis. In: Nissenson AR, Fine RN, Gentile DE, and Eds. Clinical Dialysis, 3rd edition Norwalk CT: Appleton & Lange, 1995: 343-375
  7. Gotch FA, Lipps BJ, Keen ML, Panlilio F. Computerized urea kinetic modeling to prescribe and monitor delivered Kt/V (pKt/V, dKt/V) in peritoneal dialysis. Adv Perit Dial 12:43-45, 1996
  8. Mooraki A , Kliger A, Gorban-Brennan NL, et al. Weekly Kt/V urea and selected outcome criteria in 56 randomly selected CAPD patients. Adv Perit Dial 9:92-96, 1993
  9. Busch S, Schreiber M, Bodnar D, et al. The 24-hour D/P ratio is a convenient screen for identifying altered peritoneal transport rates. Adv Perit Dial 9:119-123, 1993
  10. Haraldsson B. Assessing the peritoneal dialysis capacities of individual patients. Kidney Int 47:1187-1198, 1995
  11. Rippe B, Stelin G, Haraldsson B. Computer simulations of peritoneal fluid transport in CAPD. Kidney Int 40:315-325, 1991
  12. Van Biesen W, Carlsson O, Bergia R, et al. Personal dialysis capacity (PDCTM) test: a multicentre clinical study. Nephrol Dial Transplant 18:788-796, 2003
  13. Rocco MV, Jordan JR, Burkart JM. Determination of peritoneal transport characteristics with 24-hour dialysate collections:  Dialysis adequacy and transport test. J Am Soc Nephrol 5:1333-1338, 1994
  14. Rocco MV, Jordan JR, Burkart JM. 24-hour dialysate collection for determination of peritoneal membrane transport characteristics: Longitudinal follow-up data for the dialysis adequacy and transport test (DATT). Perit Dial Int 16:590-593, 1996
  15. Paniagua R, Amato D, Correa-Rotter R, et al. Correlation between peritoneal equilabration test and dialysis adequacy and transport test, for peritoneal transport type characterization. Perit Dial Int 20:53-59, 2000
  16. Verger C, Larpent L, Veniez G, et al. L'APEX...description et utilisation. Bull Dial Perit 1:36-40, 1991
  17. Panneekeet MM, Imholz ALT, Koomen GCM, et al.  The standard peritoneal permeability analysis: A tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 48:466, 1995
  18. Johnson DW, Mudge DW, Blizzard S, et al. A comparison of peritoneal equilibration tests performed 1 and 4 weeks after PD commencement. Perit Dial Int 24:460-465, 2004
  19. Bouts AH, Davin JC, Groothoff JW, et al. Standard peritoneal permeability analysis in children. J Am Soc Nephrol 11:943-950, 2000
  20. National Kidney Foundation. K/DOQI Clinical practice guidelines for peritoneal dialysis adequacy, 2000. Am J Kidney Disease 37(Suppl 1):S65-136, 2001
Print  Syndicate  
© 2006-2012, Fresenius Medical Care North America. All Rights Reserved. | Terms of Use | Privacy Statement | Register | Login